Public Company



Invitae is building the genetics platform to support a new age in medicine. Using the power of genomic information, we are entering an era that relies less on symptom reporting by patients and trial-and-error treatment by doctors—and more on knowing the facts about a person’s risks and biology so they can take steps to stay healthy longer and get healthy faster. We’re the one company delivering the continuum of information needed to support the healthcare system and patients from birth to old age.


Founded 2010
Type Public
Location San Francisco, California, USA


NVTA $1.24 -6.44% $(0.09)

Latest News

4 Penny Stocks To Buy For Under $5 With Unusual Options Action Mar 13, 2023 PennyStocks Unusual options activity put these penny stocks on watch lists this week. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options...
Exact Sciences' Shift In Strategy: Targeting Positive Adjusted EBITDA Mar 02, 2023 Seeking Alpha Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. Here's my take...
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Mar 01, 2023 Benzinga Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia....
Invitae (NVTA) Q4 2022 Earnings Call Transcript Mar 01, 2023 The Motley Fool NVTA earnings call for the period ending December 31, 2022.
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates Mar 01, 2023 Zacks Investment Research Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what...